112 related articles for article (PubMed ID: 1567662)
1. Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group.
Hürny C; Bernhard J; Gelber RD; Coates A; Castiglione M; Isley M; Dreher D; Peterson H; Goldhirsch A; Senn HJ
Eur J Cancer; 1992; 28(1):118-24. PubMed ID: 1567662
[TBL] [Abstract][Full Text] [Related]
2. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group.
Hürny C; Bernhard J; Coates AS; Castiglione-Gertsch M; Peterson HF; Gelber RD; Forbes JF; Rudenstam CM; Simoncini E; Crivellari D; Goldhirsch A; Senn HJ
Lancet; 1996 May; 347(9011):1279-84. PubMed ID: 8622502
[TBL] [Abstract][Full Text] [Related]
3. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.
Bernhard J; Hürny C; Coates AS; Peterson HF; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Senn HJ; Rudenstam CM
Ann Oncol; 1997 Sep; 8(9):825-35. PubMed ID: 9358933
[TBL] [Abstract][Full Text] [Related]
4. Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group.
Hürny C; Bernhard J; Coates A; Castiglione M; Peterson HF; Gelber RD; Rudenstam CM; Goldhirsch A; Senn HJ
Ann Oncol; 1994 Jan; 5(1):65-74. PubMed ID: 8172795
[TBL] [Abstract][Full Text] [Related]
5. The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG).
Hürny C; Bernhard J; Bacchi M; van Wegberg B; Tomamichel M; Spek U; Coates A; Castiglione M; Goldhirsch A; Senn HJ
Support Care Cancer; 1993 Jul; 1(4):200-8. PubMed ID: 8193882
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.
Coates AS; Hürny C; Peterson HF; Bernhard J; Castiglione-Gertsch M; Gelber RD; Goldhirsch A
J Clin Oncol; 2000 Nov; 18(22):3768-74. PubMed ID: 11078489
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial.
Hürny C; Bernhard J; Coates A; Peterson HF; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Goldhirsch A; Senn HJ
Med Care; 1996 Mar; 34(3):234-48. PubMed ID: 8628043
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
9. Quality of life assessment in the International Breast Cancer Study Group: past, present, and future.
Hürny C; Bernhard J; Coates A
Recent Results Cancer Res; 1998; 152():390-5. PubMed ID: 9928574
[TBL] [Abstract][Full Text] [Related]
10. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).
Bernhard J; Hürny C; Coates AS; Peterson HF; Castiglione-Gertsch M; Gelber RD; Galligioni E; Marini G; Thürlimann B; Forbes JF; Goldhirsch A; Senn HJ; Rudenstam CM
Br J Cancer; 1998 Sep; 78(5):686-93. PubMed ID: 9744512
[TBL] [Abstract][Full Text] [Related]
12. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.
Gelber RD; Goldhirsch A; Cavalli F
Ann Intern Med; 1991 Apr; 114(8):621-8. PubMed ID: 2003707
[TBL] [Abstract][Full Text] [Related]
13. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.
Lee CK; Stockler MR; Coates AS; Gebski V; Lord SJ; Simes RJ;
Br J Cancer; 2010 Apr; 102(9):1341-7. PubMed ID: 20389302
[TBL] [Abstract][Full Text] [Related]
14. Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data.
Bernhard J; Peterson HF; Coates AS; Gusset H; Isley M; Hinkle R; Gelber RD; Castiglione-Gertsch M; Hürny C
Stat Med; 1998 Mar 15-Apr 15; 17(5-7):587-601. PubMed ID: 9549808
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group.
Coates A; Gebski V; Signorini D; Murray P; McNeil D; Byrne M; Forbes JF
J Clin Oncol; 1992 Dec; 10(12):1833-8. PubMed ID: 1453197
[TBL] [Abstract][Full Text] [Related]
16. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
Bernhard J; Castiglione-Gertsch M; Schmitz SF; Thürlimann B; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
Eur J Cancer; 1999 Jun; 35(6):913-20. PubMed ID: 10533471
[TBL] [Abstract][Full Text] [Related]
18. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
Jones SE; Cantrell J; Vukelja S; Pippen J; O'Shaughnessy J; Blum JL; Brooks R; Hartung NL; Negron AG; Richards DA; Rivera R; Holmes FA; Chittoor S; Whittaker TL; Bordelon JH; Ketchel SJ; Davis JC; Ilegbodu D; Kochis J; Asmar L
J Clin Oncol; 2007 Oct; 25(30):4765-71. PubMed ID: 17947724
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
